Q1 2026 sales reached €1,527K (excluding licensing), an increase of +68% at Constant Exchange Rate (CER) and +57% as reported
U.S. sales grew +34% CER (+21% reported) and +51% on an invoiced basis, anchored by ongoing clinical adoption in the pancreatic cyst indication
International growth reached +326%, fueled by strong demand for CellTolerance®
Webinar for shareholders and investors – Wednesday, April 22 2026
5:45 p.m. (CET) – French Session : Click here to register
6:30 p.m. (CET) – English Session : Click here to register
Paris and Boston, April 15, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the first quarter of 2026.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented:
“Our Q1 2026 performance confirms the robust growth trajectory initiated in the U.S. in 2025, which is now expanding internationally. This momentum reinforces the growing evidence of clinical and commercial adoption of Cellvizio, as the standard of care for the evaluation of pancreatic cysts and subsequent management of patients at risk for pancreatic cancer. In addition, our investments in CellTolerance are yielding tangible results, including the U.S. launch of a premier food intolerance reference center in Southern California and the signing of two new U.S. pay-per-use accounts in the Midwest and East Coast. Likewise, we are gratified with the international response to this significant unmet medical need, including an additional CellTolerance-dedicated site in Germany. As we progress through 2026, the entire Mauna Kea organization remains laser-focused on operational discipline, balance sheet management, and scaling our commercial activity to ensure this strong start translates into sustained, profitable, long-term growth.”
For additional details and financial results, please see the full press release.
